{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:57:52Z","timestamp":1782842272660,"version":"3.54.5"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2001,8,1]],"date-time":"2001-08-01T00:00:00Z","timestamp":996624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2001,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The efficacies of orally (p.o.) dosed linezolid and intravenously (i.v.) dosed vancomycin against methicillin-resistant\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            (MRSA) in rabbits with experimental aortic-valve endocarditis were investigated. After endocarditis was established with a recent clinical MRSA isolate, rabbits were dosed for 5 days with linezolid (p.o., three times a day) at either 25, 50, or 75 mg\/kg of body weight or vancomycin (i.v., twice a day) at 25 mg\/kg. The 25-mg\/kg linezolid group had a high mortality rate and bacterial counts in the valve vegetations that were not different from those of the controls. Linezolid dosed p.o. at 50 and 75 mg\/kg and i.v. vancomycin produced statistically significant reductions in bacterial counts compared to those of the untreated controls. The reduced bacterial counts and culture-negative valve rates for the animals treated with linezolid at 75 mg\/kg were similar to those for the vancomycin-treated animals. Concentrations of linezolid in plasma were determined at several points in the dosing regimen. These results suggest that the efficacy of linezolid in this infection model is related to trough levels in plasma that remain above the MIC for this microorganism. At the ineffective dose of linezolid (25 mg\/kg) the concentration at sacrifice was 0.045 times the MIC, whereas the concentrations of linezolid in plasma in the 50- and 75-mg\/kg groups were 2 and 5 times the MIC at sacrifice, respectively. The results from this experimental model suggest that the oxazolidinone linezolid may be effective for the treatment of serious staphylococcal infections when resistance to other antimicrobials is present.\n          <\/jats:p>","DOI":"10.1128\/aac.45.8.2304-2308.2001","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:06:42Z","timestamp":1027764402000},"page":"2304-2308","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":67,"title":["Efficacy of Linezolid in Treatment of Experimental Endocarditis Caused by Methicillin-Resistant\n            <i>Staphylococcus aureus<\/i>"],"prefix":"10.1128","volume":"45","author":[{"given":"Charlene F.","family":"Dailey","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Pharmacology,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Dileto-Fang","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Pharmacology,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis V.","family":"Buchanan","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Pharmacology,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha P.","family":"Oramas-Shirey","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Pharmacology,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald H.","family":"Batts","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Global Medical Affairs-Infectious Disease U.S.,2 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles W.","family":"Ford","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Biology I,3 Pharmacia, Kalamazoo, Michigan 49001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Gibson","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Pharmacology,1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.10.2565"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00003246-199912001-00042","article-title":"Critical care patients with significant, resistant, gram-positive infections enrolled in the linezolid compassionate use protocol.","volume":"27","author":"Birmingham M. C.","year":"1999","unstructured":"Birmingham M. C. Craig R. R. Hafkin B. Todd W. M. Flavin S. M. Root J. D. Zimmer G. S. Batts D. H. Schentag J. J. Critical care patients with significant, resistant, gram-positive infections enrolled in the linezolid compassionate use protocol. Crit. Care Med. 27(12)(Suppl. S) 1999 42","journal-title":"Crit. Care Med."},{"key":"e_1_3_2_4_2","first-page":"163","article-title":"Impact of the antibiotic dosage schedule on efficacy in experimental endocarditis.","volume":"74","author":"Carbon C.","year":"1991","unstructured":"Carbon C. Impact of the antibiotic dosage schedule on efficacy in experimental endocarditis. Scand. J. Infect. Dis. 74 1991 163 172","journal-title":"Scand. J. Infect. Dis."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/44.suppl_1.31","article-title":"Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci.","volume":"44","author":"Carbon C.","year":"1999","unstructured":"Carbon C. Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci. J. Antimicrob. Chemother. 44 1999 31 36","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jac\/30.suppl_A.117","article-title":"Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus.","volume":"30","author":"Chambers H. F.","year":"1992","unstructured":"Chambers H. F. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 30 (Suppl. A) 1992 117 122","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1086\/313597","article-title":"Use of linezolid, an oxazolidinone in the treatment of multidrug-resistant gram-positive bacterial infections.","volume":"30","author":"Chien J. W.","year":"2000","unstructured":"Chien J. W. Kucia M. L. Salata R. A. Use of linezolid, an oxazolidinone in the treatment of multidrug-resistant gram-positive bacterial infections. Clin. Infect. Dis. 30 2000 146 151","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.4.953"},{"key":"e_1_3_2_9_2","first-page":"44","article-title":"Experimental bacterial endocarditis. I. Colonization of a sterile vegetation.","volume":"53","author":"Durack D. T.","year":"1972","unstructured":"Durack D. T. Beeson P. B. Experimental bacterial endocarditis. I. Colonization of a sterile vegetation. Br. J. Exp. Pathol. 53 1972 44 49","journal-title":"Br. J. Exp. Pathol."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/jac\/45.6.797","article-title":"Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors.","volume":"45","author":"Fines M.","year":"2000","unstructured":"Fines M. Leclercq R. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J. Antimicrob. Chemother. 45 2000 797 802","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.1.135"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.2.421"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000239432","article-title":"Sparfloxacin therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.","volume":"42","author":"Maserati R.","year":"1996","unstructured":"Maserati R. Cagni A. E. Segu C. Sparfloxacin therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Chemotherapy 42 1996 133 139","journal-title":"Chemotherapy"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1086\/313669","article-title":"Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with Synercid (quinupristin\/dalfopristin).","volume":"30","author":"McNeil A.","year":"2000","unstructured":"McNeil A. Clark N. M. Chandrasekar P. H. Kauffman C. A. Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with Synercid (quinupristin\/dalfopristin). Clin. Infect. Dis. 30 2000 403 404","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/jac\/44.3.415","article-title":"In-vitro activities of 11 antibiotics against vancomycin-resistant enterococci isolated in Japan.","volume":"44","author":"Miyazaki S.","year":"1999","unstructured":"Miyazaki S. Ishii Y. Ohno A. Furuya N. Matsumoto T. Tateda K. Yamaguchi K. In-vitro activities of 11 antibiotics against vancomycin-resistant enterococci isolated in Japan. J. Antimicrob. Chemother. 44 1999 415 420","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_16_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Performance standards for antimicrobial susceptibility testing. M7\u2013A4.\n          1997\n          National Committee for Clinical Laboratory Standards\n          Wayne Pa"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/jac\/47.3.349","article-title":"Efficacy of linezolid in a staphylococcal endocarditis rabbit model.","volume":"47","author":"Oramas-Shirey M. P.","year":"2001","unstructured":"Oramas-Shirey M. P. Buchanan L. V. Dileto-Fang C. L. Dailey C. F. Ford C. W. Batts D. H. Gibson J. K. Efficacy of linezolid in a staphylococcal endocarditis rabbit model. J. Antimicrob. Chemother. 47 2001 349 352","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3201\/eid0501.990118","article-title":"Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia.","volume":"5","author":"Rotun S. S.","year":"1999","unstructured":"Rotun S. S. McMath V. Schoonamaker D. J. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg. Infect. Dis. 5 1999 147 149","journal-title":"Emerg. Infect. Dis."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.721"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199902183400701"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.12.3251"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.8.2304-2308.2001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.45.8.2304-2308.2001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:04:47Z","timestamp":1645463087000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.45.8.2304-2308.2001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["10.1128\/AAC.45.8.2304-2308.2001"],"URL":"https:\/\/doi.org\/10.1128\/aac.45.8.2304-2308.2001","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8]]},"assertion":[{"value":"2000-12-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-05-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2001-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}